111 related articles for article (PubMed ID: 26977999)
1. Target Enzyme Activity and Phosphorylation of Pathway Molecules As Specific Biomarkers in Transplantation.
Budde K; Sommerer C; Rissling O; Dieterlen MT; Barten MJ
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S43-9. PubMed ID: 26977999
[TBL] [Abstract][Full Text] [Related]
2. Assay validation of phosphorylated S6 ribosomal protein for a pharmacodynamic monitoring of mTOR-inhibitors in peripheral human blood.
Dieterlen MT; Bittner HB; Klein S; von Salisch S; Mittag A; Tárnok A; Dhein S; Mohr FW; Barten MJ
Cytometry B Clin Cytom; 2012 May; 82(3):151-7. PubMed ID: 22213594
[TBL] [Abstract][Full Text] [Related]
3. Target enzyme activity as a biomarker for immunosuppression.
Glander P; Budde K
Ther Drug Monit; 2010 Jun; 32(3):257-60. PubMed ID: 20431505
[TBL] [Abstract][Full Text] [Related]
4. Improved assay for the nonradioactive determination of inosine 5'-monophosphate dehydrogenase activity in peripheral blood mononuclear cells.
Glander P; Sombogaard F; Budde K; van Gelder T; Hambach P; Liefeldt L; Lorkowski C; Mai M; Neumayer HH; Vulto AG; Mathot RA
Ther Drug Monit; 2009 Jun; 31(3):351-9. PubMed ID: 19333146
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous quantification of IMPDH activity and purine bases in lymphocytes using LC-MS/MS: assessment of biomarker responses to mycophenolic acid.
Vethe NT; Ali AM; Reine PA; Andersen AM; Bremer S; Line PD; Rootwelt H; Bergan S
Ther Drug Monit; 2014 Feb; 36(1):108-18. PubMed ID: 24061448
[TBL] [Abstract][Full Text] [Related]
6. Inosine 5'-monophosphate dehydrogenase activity as a biomarker in the field of transplantation.
Glander P; Hambach P; Liefeldt L; Budde K
Clin Chim Acta; 2012 Sep; 413(17-18):1391-7. PubMed ID: 21889500
[TBL] [Abstract][Full Text] [Related]
7. Development and application of a high-performance liquid chromatography-based assay for determination of the activity of inosine 5'-monophosphate dehydrogenase in whole blood and isolated mononuclear cells.
Albrecht W; Storck M; Pfetsch E; Martin W; Abendroth D
Ther Drug Monit; 2000 Jun; 22(3):283-94. PubMed ID: 10850395
[TBL] [Abstract][Full Text] [Related]
8. Optimization and application of an HPLC method for quantification of inosine-5'-monophosphate dehydrogenase activity as a pharmacodynamic biomarker of mycophenolic acid in Chinese renal transplant patients.
Liu F; Xu L; Sheng C; Qiu X; Zhang M; Jiao Z
Clin Chim Acta; 2018 Oct; 485():333-339. PubMed ID: 29964005
[TBL] [Abstract][Full Text] [Related]
9. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
Vethe NT; Bergan S
Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
[TBL] [Abstract][Full Text] [Related]
10. Development of a sensitive phospho-p70 S6 kinase ELISA to quantify mTOR proliferation signal inhibition.
Hartmann B; He X; Keller F; Fischereder M; Guba M; Schmid H
Ther Drug Monit; 2013 Apr; 35(2):233-9. PubMed ID: 23503450
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.
Maiguma T; Yosida T; Otsubo K; Okabe Y; Sugitani A; Tanaka M; Oishi R; Teshima D
J Clin Pharm Ther; 2010 Feb; 35(1):79-85. PubMed ID: 20175815
[TBL] [Abstract][Full Text] [Related]
12. Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition.
Abdel-Kahaar E; Kabakchiev M; Hartmann B; Wieland E; Shipkova M
Clin Biochem; 2016 Oct; 49(15):1181-1187. PubMed ID: 27372285
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.
Vethe NT; Bremer S; Rootwelt H; Bergan S
Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic Monitoring of mTOR Inhibitors.
Millán O; Wieland E; Marquet P; Brunet M
Ther Drug Monit; 2019 Apr; 41(2):160-167. PubMed ID: 30883509
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of inosine monophosphate dehydrogenase activity as a biomarker for mycophenolic acid effect: potential clinical implications.
Weimert NA; Derotte M; Alloway RR; Woodle ES; Vinks AA
Ther Drug Monit; 2007 Apr; 29(2):141-9. PubMed ID: 17417067
[TBL] [Abstract][Full Text] [Related]
16. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic monitoring of mycophenolate mofetil.
Budde K; Glander P; Bauer S; Braun K; Waiser J; Fritsche L; Mai I; Roots I; Neumayer HH
Clin Chem Lab Med; 2000 Nov; 38(11):1213-6. PubMed ID: 11156363
[TBL] [Abstract][Full Text] [Related]
18. [The determination and clinical application of inosine 5’-monophosphate dehydrogenase activity].
Liu FY; Qiu XY; Jiao Z
Yao Xue Xue Bao; 2016 Nov; 51(11):1666-73. PubMed ID: 29908108
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.
Reine PA; Vethe NT; Kongsgaard UE; Andersen AM; Line PD; Ali AM; Bergan S
Scand J Clin Lab Invest; 2013 Mar; 73(2):117-24. PubMed ID: 23281843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
